Health authorities are initiating a coordinated research effort to standardize clinical trials for near-infrared photobiomodulation therapy, aiming to validate its efficacy in accelerating burn repair and its potential neuropsychiatric applications. With promising preliminary results aligning across multiple analytical pillars, this low-to-moderate risk intervention highlights the importance of wavelength selection and dosing. As further evidence emerges, a phased rollout based on safety and efficacy is anticipated, potentially transforming treatment protocols for burns and brain-related disorders.